Developer docs
API playgroundTry for free, no card

Search company profiles

Dyno Therapeutics

Full company profile

uuid0000d6r

Namestring
Dyno Therapeutics
Legal namestring
Dyno Therapeutics, Inc.
Websiteurl
dynotx.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Dyno Therapeutics is a privately held, venture-backed biotechnology company founded in 2018 that applies artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) capsid delivery vectors for gene therapy. The company's foundational technology is the CapsidMap platform, which pairs high-throughput in vivo DNA multiplexing experimentation (producing billions of sequence-function data points per month) with ML-guided search algorithms to navigate capsid sequence space, supplemented by the LEAP (Low-shot Efficient Accelerated Performance) technology that generates out-of-distribution capsid variants. The company has launched nine AI-engineered capsids across three therapeutic areas: brain/CNS (Dyno-9zh, Dyno-yp2, Dyno-ahq, Dyno-hc9), muscle and neuromuscular (Dyno-bn8, Dyno-n96, Dyno-3hv), and eye (Dyno-4z2, Dyno-86m), with multiple capsids demonstrating 25x-280x performance improvements versus wild-type AAV9 in preclinical models.

Dyno operates a partnership-centric business model rather than developing its own therapeutics, commercializing its capsid platform through collaboration and license agreements with gene therapy developers including Roche, Astellas, Sarepta, Novartis, and NVIDIA. Revenue is generated through upfront payments, license exercise fees, research-phase payments, and clinical/regulatory/sales milestone payments, plus royalties on any commercialized products developed by partners using Dyno capsids. Cumulative disclosed deal value exceeds several billion dollars in potential milestones across all partnerships. In March 2026, Dyno extended its platform with Dyno Psi-Phi, a protein binder design suite comprising Dyno Phi (experimentally calibrated filters), Dyno Psi-1 (open-weight generative model trained on NVIDIA DGX Cloud), REST APIs at design.dynotx.com, and Claude Code Skills, broadening the company's scope beyond capsid engineering. The Dyno Frontiers Network, a curated ecosystem of 15 therapeutic developers, 7 manufacturers, 6 service providers, and 15 investor partners, supports developers with no-cost research access to capsids and downstream execution resources. The company is led by Cofounder and CEO Eric Kelsic, with cofounders from George Church's Harvard/Wyss lab including CSO Adrian Veres, VP ML Sam Sinai, and Executive Chairman Alan Crane.

Short descriptiontext

Dyno Therapeutics designs AI-engineered AAV capsids for gene therapy through its CapsidMap platform, licensing optimized delivery vectors to therapeutic developers including Roche, Astellas, Sarepta, and Novartis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI gene therapy, AAV capsid design, viral vector engineering, protein binder design, AI drug discovery
Industry5 codes
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
AI-Designed AAV Gene Therapy Vectors
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments from Therapeutic Partners
TypeLicensing Royalties
Description

Revenue generated from collaboration and license agreements with gene therapy developers (Roche, Astellas, Sarepta, Novartis). Includes upfront cash payments, option/license exercise fees, research-phase payments, and clinical/regulatory/sales milestone payments tied to progression of partnered programs. Royalties on net sales of commercialized products are also received.

dynotx.com
2One-Time License Exercise Fees
TypeOne Time License
Description

Discrete payments when partners exercise options to license a specific capsid (e.g., $15M from Astellas in April 2026 for skeletal muscle capsid; $7M from Roche in January 2025 for neurological disease capsid).

dynotx.com
3Royalties on Net Sales
TypeLicensing Royalties
Description

Ongoing royalty payments on worldwide net sales of any commercial products developed by partners using Dyno capsids.

dynotx.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details3 tiers
1Custom negotiated partnership agreements (upfront fees, milestones, royalties)
ModelOtherBilling cadenceMulti-year contract
Notes

Not publicly disclosed. Deal-by-deal bilateral negotiation with each therapeutic partner. Deal-by-deal bilateral negotiation; not publicly disclosed.

dynotx.com
2Free / no-cost access via Dyno Frontiers Network for qualifying developers
ModelFreemiumBilling cadencePay-as-you-go
Notes

No-cost, non-exclusive research access to Dyno capsids for therapeutic developers, with advisory support and access to manufacturing/service/investor partners.

dynotx.com
3Free community-tier access to Dyno Psi-Phi APIs, Claude Code Skills, and open-weight models
ModelFreemiumBilling cadencePay-as-you-go
Notes

Dyno Psi-Phi APIs and open-weight Dyno Psi-1 model are available to the developer community free of charge; access to design.dynotx.com and Hugging Face.

dynotx.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 5 records shown
1CapsidMap
Description

Dyno's proprietary AI-powered platform for the design of novel adeno-associated virus (AAV) capsids for gene therapy, applying DNA library synthesis, next-generation DNA sequencing, and machine learning to measure and optimize in vivo gene delivery properties.

dynotx.com
+4 more records
Core offering1 text field

Dyno Therapeutics applies artificial intelligence and high-throughput in vivo experimentation to design optimized adeno-associated virus (AAV) capsid delivery vectors for gene therapy. The company designs, licenses, and partners AI-engineered capsids targeting the brain, muscle, and eye to gene therapy developers under collaboration and license agreements that include upfront fees, milestone payments, and royalties. Dyno also offers the Dyno Psi-Phi protein design suite, including open-weight generative models and APIs for protein binder design.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • Dyno-yp2 achieves 113x higher brain transduction vs AAV9 in humanized TfR1 mice at 2e13 vg/kg with 29x lower liver biodistribution than AAV9 and 80x lower than BI-hTFR1
+9 more records
Product overview1 text field

Dyno Therapeutics operates a partnership-centric platform business built around its proprietary CapsidMap AI platform, which combines frontier AI models with high-throughput in vivo experimentation to design optimized AAV capsid delivery vectors. The core platform is enhanced by the LEAPSM (Low-shot Efficient Accelerated Performance) sub-technology. The company offers a portfolio of nine AI-engineered individual capsid products organized by tissue target: brain (Dyno-9zh, Dyno-yp2, Dyno-ahq, Dyno-hc9), muscle/neuromuscular (Dyno-bn8, Dyno-n96, Dyno-3hv), and eye (Dyno-4z2, Dyno-86m), each available for direct licensing. Building on the capsid platform, Dyno launched Dyno Psi-Phi, a generative protein binder design suite comprising Dyno Phi (filtering tools that predict real-world outcomes) and Dyno Psi-1 (an open-weight generative protein binder design model), all exposed through Dyno Psi-Phi REST APIs at design.dynotx.com and via Dyno Psi-Phi Claude Code Skills. The Dyno Frontiers Network program connects gene therapy developers with these capsids alongside manufacturing, service, and investor partners.

Product and service10 records
1Dyno Psi-Phi
CategoryAI Protein Design Platform
Description

Suite of AI-powered protein design tools that includes Dyno Phi (filters predicting real-world experimental outcomes), Dyno Psi-1 (open-weight generative protein binder design model), Dyno Psi-Phi REST APIs, and Dyno Psi-Phi Claude Code Skills. Designed for therapeutic developers, computational biologists, and rare disease researchers to generate and evaluate protein binder designs programmatically.

2Dyno-9zh
CategoryAAV Capsid (CNS Delivery)
Description

AI-engineered AAV capsid for CNS delivery that crosses the blood-brain barrier by binding the human Alkaline Phosphatase (ALPL) receptor, achieving up to 50% neuronal transduction in NHP cortex at 3e13 vg/kg with greater than 10x lower liver biodistribution than AAV9. Best-performing ALPL-targeting capsid when compared head-to-head in mouse and NHP.

3Dyno-yp2
CategoryAAV Capsid (CNS Delivery)
Description

TfR1-mediated AAV capsid for CNS delivery that binds the human transferrin receptor to cross the blood-brain barrier, achieving greater than 94% neuronal transduction in TfR-humanized mice with 113x higher brain transduction vs AAV9, 29x lower liver biodistribution than AAV9, and 80x lower liver biodistribution than BI-hTFR1.

4Dyno-ahq
CategoryAAV Capsid (CNS Delivery)
Description

AAV capsid optimized for widespread IV delivery to the brain, reaching up to 30% of NHP neurons at 3e13 vg/kg with 280x higher brain transduction and 50x lower liver transduction vs AAV9. Engages a highly conserved candidate receptor supporting translation to humans.

5Dyno-hc9 (bCap 1)
CategoryAAV Capsid (CNS Delivery)
Description

First Dyno capsid optimized for highly efficient delivery across the blood-brain barrier, achieving 100x higher brain transduction and 10x lower liver transduction vs AAV9, with broad CNS tropism reaching deep brain regions and spinal cord.

6Dyno-bn8
CategoryAAV Capsid (Muscle Delivery)
Description

AAV capsid for skeletal and cardiac muscle delivery at IV doses as low as 5e12 vg/kg (25x lower than Elevidys), transducing 73-88% of myofibers in NHP skeletal muscles and 35-42% of cardiac cells. Compatible with AAV9-based manufacturing processes and licensed by Astellas in April 2026.

7Dyno-n96
CategoryAAV Capsid (Muscle Delivery)
Description

AAVrh74-based AAV capsid for skeletal and cardiac muscle delivery at 5e12 vg/kg, transducing 74% of myofibers in NHP skeletal muscles with low liver biodistribution. Compatible with AAV9 and AAVrh74 production processes.

8Dyno-3hv
CategoryAAV Capsid (Neuromuscular Delivery)
Description

First capsid optimized for highly efficient delivery to multiple tissues affected by neuromuscular disorders, including heart, skeletal muscle, and CNS. Transduces 50-90% of myofibers in NHP skeletal muscles at doses as low as 4e12 vg/kg.

9Dyno-4z2
CategoryAAV Capsid (Eye Delivery)
Description

AAV capsid optimized for highly efficient delivery to the retina through intravitreal injection, achieving greater than 40x retinal transduction vs AAV2 and 5x bipolar cell transduction vs an externally engineered reference capsid. Ideal for optogenetic gene therapies.

10Dyno-86m (eCap 1)
CategoryAAV Capsid (Eye Delivery)
Description

First Dyno ocular capsid, optimized for highly efficient delivery to the retina through intravitreal injection with broad retinal tropism. Achieves 80x higher retinal transduction vs AAV2.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership21 partners
Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-13
Description

Manufacturing partner in the Dyno Frontiers Network with proven experience producing Dyno capsids.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-13
Description

Manufacturing partner in the Dyno Frontiers Network.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-13
Description

Manufacturing partner in the Dyno Frontiers Network.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-13
Description

Manufacturing partner in the Dyno Frontiers Network.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-13
Description

Manufacturing partner in the Dyno Frontiers Network.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

Service provider in the Dyno Frontiers Network.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

Service provider in the Dyno Frontiers Network.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

CRO partner in the Dyno Frontiers Network with expertise in AAV gene therapy and Dyno's platform.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

Service provider in the Dyno Frontiers Network.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

Regulatory consultant in the Dyno Frontiers Network with AAV gene therapy expertise.

Strategic tierSecondaryTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-05-13
Description

Regulatory consultant in the Dyno Frontiers Network with AAV gene therapy expertise.

12Y Combinator
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Startup accelerator partner in the Dyno Frontiers Network for companies incubating in Y Combinator.

dynotx.com
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2026-03-18
Description

Anthropic integration: Dyno Psi-Phi is available as Claude Code Skills, providing authenticated access to Dyno's GPU-backed APIs directly within Anthropic's Claude Code. Dyno participated in beta testing of Anthropic's Claude Fable 5 model for AAV vector design.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-11-11
Description

Trisk Bio is the first manufacturing partner in Dyno's Frontiers Program, announced in November 2025 at GATC 2025. Trisk provides scalable, high-purity AAV production services for Dyno capsids, helping gene therapy developers reduce costs and accelerate development. Trisk has also onboarded the Dyno-yp2 capsid.

Strategic tierSecondaryTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-11
Description

Manufacturing partner in the Dyno Frontiers Network providing AAV production services for Dyno capsids.

Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2024-05-09
Description

NVIDIA and Dyno collaboration announced in May 2024 to leverage Dyno's AI and in vivo capabilities with NVIDIA's BioNeMo platform, NIM microservices, and accelerated computing for biological sequence design. The collaboration co-developed the open-source BioNeMo Framework (released November 2024). In March 2026, Dyno and NVIDIA jointly launched Dyno Psi-Phi at NVIDIA GTC 2026, including Dyno Psi-1 trained on NVIDIA DGX Cloud using Hopper GPUs and integration with NVIDIA Transformer Engine.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-12-01
Description

Astellas entered a research collaboration with Dyno in December 2021 to develop next-generation AAV gene therapy vectors for skeletal and cardiac muscle. Dyno received $18M upfront and is eligible for milestone and royalty payments potentially exceeding $1.6B. In April 2026, Astellas exercised its option to license a Dyno capsid for skeletal muscle-targeted gene delivery ($15M license fee plus milestones and royalties), making Dyno the first company to license an AI-designed AAV capsid for both CNS and muscle gene therapies.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2020-10-14
Description

Roche entered into a collaboration and license agreement with Dyno in October 2020 to apply CapsidMap for CNS and liver-directed AAV gene therapies. Aggregate potential milestone payments may exceed $1.8B. In January 2025, Roche exercised an option to license a Dyno capsid for a neurological disease indication ($7M option fee plus up to $220M+ in milestones plus royalties). In October 2024, the companies entered a new $50M upfront CNS partnership with over $1B in potential milestones plus royalties. Roche is also building on Dyno's LEAP technology.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-05-11
Description

Sarepta and Dyno announced a partnership in May 2020 to develop next-generation AAV vectors for muscle diseases using Dyno's CapsidMap platform. Dyno could receive over $40M in upfront, option and license payments during the research phase, with additional significant future milestone payments and royalties on worldwide net sales. Partnership completed in 2025 with improved capsids developed.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-05-11
Description

Novartis and Dyno announced an ocular collaboration in May 2020 to develop improved AAV vectors for gene therapies for ocular diseases. Financial terms include upfront consideration, research funding, license fees, clinical and sales milestone payments, and royalties. Partnership completed in 2024 with improved capsids developed.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2018-05-01
Description

Dyno was founded in 2018 on technology developed in George Church's lab at the Wyss Institute for Biologically Inspired Engineering, Harvard Medical School. Dyno has an exclusive option to license the underlying technology from Harvard University, including IP around the comprehensive AAV capsid fitness landscape (Science 2019 publication). George Church, Tomas Bjorklund, and other Harvard scientists serve as Dyno cofounders or scientific advisors.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage gene therapy company engineering proprietary AAV capsids (e.g., 4D-150, 4D-710, 4D-175) for ophthalmology, pulmonology, and cardiology. Closest direct competitor to Dyno in machine-guided AAV capsid design, with multiple partnered and wholly-owned programs and similar deal structures.

TypeDirect peer
Description

AI-driven AAV capsid engineering company developing novel vectors for CNS, muscle, and cardiac indications. Builds engineered capsids using high-throughput data and computation, with similar partnership-plus-pipeline business model to Dyno.

TypeDirect peer
Description

Clinical-stage gene therapy company that has historically paired its TRACER-derived AAV capsid platform with pharma partners (e.g., Pfizer, Neurocrine, Novartis) for CNS indications. Direct comparability in capsid engineering + partnership model.

TypeBroad incumbent
Description

Established AAV gene therapy platform company with proprietary NAV technology, extensive licensing business, and a wholly-owned clinical pipeline. Broader incumbent in AAV delivery, providing both licensed vectors (including to Roche, Novartis) and competing capsid IP.

TypeBroad incumbent
Description

Commercial-stage gene therapy company with AAV platform technology (HEMGENIX for hemophilia B) and a clinical pipeline in CNS and cardiovascular indications. Comparable gene therapy developer that uses and competes with various AAV capsid technologies.

TypeBroad incumbent
Description

Large pharma with significant internal AAV gene therapy programs (e.g., Beqvez for hemophilia B) and internal capsid engineering investments. Represents both a potential customer and a competitive threat to Dyno's partnership pipeline.

TypeBroad incumbent
Description

Roche is Dyno's largest partner (>$3B in potential licensing deal value) and Spark is its gene therapy arm (Luxturna). They are simultaneously major customers and developers of competing gene therapy programs using Dyno and third-party capsids.

TypeEmerging player
Description

AI-driven generative biology company designing novel protein therapeutics across multiple modalities. Overlapping AI-for-protein-design platform with Dyno Psi-Phi, though focused on therapeutic proteins rather than AAV delivery.

9Crary Group / Deciduous Therapeutics (and similar AI-bio peers)
TypeOthers
Description

Adjacent AI-driven biotech companies backed by Dyno's investor CRV. Representative of the broader AI-bio ecosystem in which Dyno operates and from which it sources investor, developer, and ecosystem partnerships through the Frontiers Network.

TypeOthers
Description

AAV-focused contract development and manufacturing organization (CDMO) and Dyno Frontiers Network manufacturing partner. Comparable ecosystem participant enabling gene therapy manufacturing, and a key distribution and production partner for Dyno's capsids.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers18 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dyno Therapeutics

AI-Designed AAV Gene Therapy Vectorsdynotx.com

Dyno Therapeutics designs AI-engineered AAV capsids for gene therapy through its CapsidMap platform, licensing optimized delivery vectors to therapeutic developers including Roche, Astellas, Sarepta, and Novartis.

What Dyno Therapeutics does

Dyno Therapeutics is a privately held, venture-backed biotechnology company founded in 2018 that applies artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) capsid delivery vectors for gene therapy. The company's foundational technology is the CapsidMap platform, which pairs high-throughput in vivo DNA multiplexing experimentation (producing billions of sequence-function data points per month) with ML-guided search algorithms to navigate capsid sequence space, supplemented by the LEAP (Low-shot Efficient Accelerated Performance) technology that generates out-of-distribution capsid variants. The company has launched nine AI-engineered capsids across three therapeutic areas: brain/CNS (Dyno-9zh, Dyno-yp2, Dyno-ahq, Dyno-hc9), muscle and neuromuscular (Dyno-bn8, Dyno-n96, Dyno-3hv), and eye (Dyno-4z2, Dyno-86m), with multiple capsids demonstrating 25x-280x performance improvements versus wild-type AAV9 in preclinical models.

Dyno operates a partnership-centric business model rather than developing its own therapeutics, commercializing its capsid platform through collaboration and license agreements with gene therapy developers including Roche, Astellas, Sarepta, Novartis, and NVIDIA. Revenue is generated through upfront payments, license exercise fees, research-phase payments, and clinical/regulatory/sales milestone payments, plus royalties on any commercialized products developed by partners using Dyno capsids. Cumulative disclosed deal value exceeds several billion dollars in potential milestones across all partnerships. In March 2026, Dyno extended its platform with Dyno Psi-Phi, a protein binder design suite comprising Dyno Phi (experimentally calibrated filters), Dyno Psi-1 (open-weight generative model trained on NVIDIA DGX Cloud), REST APIs at design.dynotx.com, and Claude Code Skills, broadening the company's scope beyond capsid engineering. The Dyno Frontiers Network, a curated ecosystem of 15 therapeutic developers, 7 manufacturers, 6 service providers, and 15 investor partners, supports developers with no-cost research access to capsids and downstream execution resources. The company is led by Cofounder and CEO Eric Kelsic, with cofounders from George Church's Harvard/Wyss lab including CSO Adrian Veres, VP ML Sam Sinai, and Executive Chairman Alan Crane.

Dyno Therapeutics firmographics

Firmographics
Name
Dyno Therapeutics
Legal name
Dyno Therapeutics, Inc.
Website
https://dynotx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Dyno Therapeutics designs AI-engineered AAV capsids for gene therapy through its CapsidMap platform, licensing optimized delivery vectors to therapeutic developers including Roche, Astellas, Sarepta, and Novartis.
Ownership category
akta.pro rank

Dyno Therapeutics industry classification

Industry
Product category
AI-Designed AAV Gene Therapy Vectors
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAI
Cardiometabolic & Other Systemic Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • AI gene therapy
  • AAV capsid design
  • Viral vector engineering
  • Protein binder design
  • AI drug discovery

Where Dyno Therapeutics is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Dyno Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments from Therapeutic Partners: Revenue generated from collaboration and license agreements with gene therapy developers (Roche, Astellas, Sarepta, Novartis). Includes upfront cash payments, option/license exercise fees, research-phase payments, and clinical/regulatory/sales milestone payments tied to progression of partnered programs. Royalties on net sales of commercialized products are also received.
  2. One-Time License Exercise Fees: Discrete payments when partners exercise options to license a specific capsid (e.g., $15M from Astellas in April 2026 for skeletal muscle capsid; $7M from Roche in January 2025 for neurological disease capsid).
  3. Royalties on Net Sales: Ongoing royalty payments on worldwide net sales of any commercial products developed by partners using Dyno capsids.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom negotiated partnership agreements (upfront fees, milestones, royalties)
FreemiumPay-as-you-goFree / no-cost access via Dyno Frontiers Network for qualifying developers
FreemiumPay-as-you-goFree community-tier access to Dyno Psi-Phi APIs, Claude Code Skills, and open-weight models

Go-to-market motion4 records

Distribution channels5 records

Marketing channels8 records

Dyno Therapeutics product offering

Product offering

Core offering

Dyno Therapeutics applies artificial intelligence and high-throughput in vivo experimentation to design optimized adeno-associated virus (AAV) capsid delivery vectors for gene therapy. The company designs, licenses, and partners AI-engineered capsids targeting the brain, muscle, and eye to gene therapy developers under collaboration and license agreements that include upfront fees, milestone payments, and royalties. Dyno also offers the Dyno Psi-Phi protein design suite, including open-weight generative models and APIs for protein binder design.

Product overview

Dyno Therapeutics operates a partnership-centric platform business built around its proprietary CapsidMap AI platform, which combines frontier AI models with high-throughput in vivo experimentation to design optimized AAV capsid delivery vectors. The core platform is enhanced by the LEAPSM (Low-shot Efficient Accelerated Performance) sub-technology. The company offers a portfolio of nine AI-engineered individual capsid products organized by tissue target: brain (Dyno-9zh, Dyno-yp2, Dyno-ahq, Dyno-hc9), muscle/neuromuscular (Dyno-bn8, Dyno-n96, Dyno-3hv), and eye (Dyno-4z2, Dyno-86m), each available for direct licensing. Building on the capsid platform, Dyno launched Dyno Psi-Phi, a generative protein binder design suite comprising Dyno Phi (filtering tools that predict real-world outcomes) and Dyno Psi-1 (an open-weight generative protein binder design model), all exposed through Dyno Psi-Phi REST APIs at design.dynotx.com and via Dyno Psi-Phi Claude Code Skills. The Dyno Frontiers Network program connects gene therapy developers with these capsids alongside manufacturing, service, and investor partners.

Differentiator

Problem solved

Functional benefit

Brands

  • CapsidMap: Dyno's proprietary AI-powered platform for the design of novel adeno-associated virus (AAV) capsids for gene therapy, applying DNA library synthesis, next-generation DNA sequencing, and machine learning to measure and optimize in vivo gene delivery properties.
  • LEAPSM (Low-shot Efficient Accelerated Performance)
  • Dyno Psi-Phi
  • Dyno Frontiers Network
  • Genetic Agency Technology Conference (GATC)

Products and services

  • Dyno Psi-Phi Suite of AI-powered protein design tools that includes Dyno Phi (filters predicting real-world experimental outcomes), Dyno Psi-1 (open-weight generative protein binder design model), Dyno Psi-Phi REST APIs, and Dyno Psi-Phi Claude Code Skills. Designed for therapeutic developers, computational biologists, and rare disease researchers to generate and evaluate protein binder designs programmatically.
  • Dyno-9zh AI-engineered AAV capsid for CNS delivery that crosses the blood-brain barrier by binding the human Alkaline Phosphatase (ALPL) receptor, achieving up to 50% neuronal transduction in NHP cortex at 3e13 vg/kg with greater than 10x lower liver biodistribution than AAV9. Best-performing ALPL-targeting capsid when compared head-to-head in mouse and NHP.
  • Dyno-yp2 TfR1-mediated AAV capsid for CNS delivery that binds the human transferrin receptor to cross the blood-brain barrier, achieving greater than 94% neuronal transduction in TfR-humanized mice with 113x higher brain transduction vs AAV9, 29x lower liver biodistribution than AAV9, and 80x lower liver biodistribution than BI-hTFR1.
  • Dyno-ahq AAV capsid optimized for widespread IV delivery to the brain, reaching up to 30% of NHP neurons at 3e13 vg/kg with 280x higher brain transduction and 50x lower liver transduction vs AAV9. Engages a highly conserved candidate receptor supporting translation to humans.
  • Dyno-hc9 (bCap 1) First Dyno capsid optimized for highly efficient delivery across the blood-brain barrier, achieving 100x higher brain transduction and 10x lower liver transduction vs AAV9, with broad CNS tropism reaching deep brain regions and spinal cord.
  • Dyno-bn8 AAV capsid for skeletal and cardiac muscle delivery at IV doses as low as 5e12 vg/kg (25x lower than Elevidys), transducing 73-88% of myofibers in NHP skeletal muscles and 35-42% of cardiac cells. Compatible with AAV9-based manufacturing processes and licensed by Astellas in April 2026.
  • Dyno-n96 AAVrh74-based AAV capsid for skeletal and cardiac muscle delivery at 5e12 vg/kg, transducing 74% of myofibers in NHP skeletal muscles with low liver biodistribution. Compatible with AAV9 and AAVrh74 production processes.
  • Dyno-3hv First capsid optimized for highly efficient delivery to multiple tissues affected by neuromuscular disorders, including heart, skeletal muscle, and CNS. Transduces 50-90% of myofibers in NHP skeletal muscles at doses as low as 4e12 vg/kg.
  • Dyno-4z2 AAV capsid optimized for highly efficient delivery to the retina through intravitreal injection, achieving greater than 40x retinal transduction vs AAV2 and 5x bipolar cell transduction vs an externally engineered reference capsid. Ideal for optogenetic gene therapies.
  • Dyno-86m (eCap 1) First Dyno ocular capsid, optimized for highly efficient delivery to the retina through intravitreal injection with broad retinal tropism. Achieves 80x higher retinal transduction vs AAV2.

Quantifiable outcome

  • Dyno-yp2 achieves 113x higher brain transduction vs AAV9 in humanized TfR1 mice at 2e13 vg/kg with 29x lower liver biodistribution than AAV9 and 80x lower than BI-hTFR1
  • +9 more outcomes

Companies that use Dyno Therapeutics

Customer profile

Named customers18 records

Segments3 records

Ideal customer profiles3 records

Dyno Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability6 records

Feature8 records

Dyno Therapeutics partnerships and signals

Strategic signal

Partnerships

21 partnerships are on record, tiered secondary, major and flagship.

  • Andelyn BiosciencessecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network with proven experience producing Dyno capsids.
  • Cirsium BiosciencessecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
  • Franklin BiolabssecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
  • PackGenesecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
  • RevvitysecondaryChannel Partner/ Reseller/ Distributor · 13 May 2026Manufacturing partner in the Dyno Frontiers Network.
  • AldevronsecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Service provider in the Dyno Frontiers Network.
  • BioAnalysis LLCsecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Service provider in the Dyno Frontiers Network.
  • Charles River LaboratoriessecondaryImplementation/ SI/ Consulting Partner · 13 May 2026CRO partner in the Dyno Frontiers Network with expertise in AAV gene therapy and Dyno's platform.
  • Curi BiosecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Service provider in the Dyno Frontiers Network.
  • Dark Horse Consulting GroupsecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Regulatory consultant in the Dyno Frontiers Network with AAV gene therapy expertise.
  • Eliquent Life SciencessecondaryImplementation/ SI/ Consulting Partner · 13 May 2026Regulatory consultant in the Dyno Frontiers Network with AAV gene therapy expertise.
  • Y CombinatorsecondaryStrategic or Co-development Partner · 13 May 2026Startup accelerator partner in the Dyno Frontiers Network for companies incubating in Y Combinator.
  • AnthropicmajorTechnology or Integration · 18 March 2026Anthropic integration: Dyno Psi-Phi is available as Claude Code Skills, providing authenticated access to Dyno's GPU-backed APIs directly within Anthropic's Claude Code. Dyno participated in beta testing of Anthropic's Claude Fable 5 model for AAV vector design.
  • Trisk BiomajorStrategic or Co-development Partner · 11 November 2025Trisk Bio is the first manufacturing partner in Dyno's Frontiers Program, announced in November 2025 at GATC 2025. Trisk provides scalable, high-purity AAV production services for Dyno capsids, helping gene therapy developers reduce costs and accelerate development. Trisk has also onboarded the Dyno-yp2 capsid.
  • 3PBioviansecondaryChannel Partner/ Reseller/ Distributor · 11 November 2025Manufacturing partner in the Dyno Frontiers Network providing AAV production services for Dyno capsids.
  • NVIDIAflagshipTechnology or Integration · 9 May 2024NVIDIA and Dyno collaboration announced in May 2024 to leverage Dyno's AI and in vivo capabilities with NVIDIA's BioNeMo platform, NIM microservices, and accelerated computing for biological sequence design. The collaboration co-developed the open-source BioNeMo Framework (released November 2024). In March 2026, Dyno and NVIDIA jointly launched Dyno Psi-Phi at NVIDIA GTC 2026, including Dyno Psi-1 trained on NVIDIA DGX Cloud using Hopper GPUs and integration with NVIDIA Transformer Engine.
  • Astellas PharmaflagshipStrategic or Co-development Partner · 1 December 2021Astellas entered a research collaboration with Dyno in December 2021 to develop next-generation AAV gene therapy vectors for skeletal and cardiac muscle. Dyno received $18M upfront and is eligible for milestone and royalty payments potentially exceeding $1.6B. In April 2026, Astellas exercised its option to license a Dyno capsid for skeletal muscle-targeted gene delivery ($15M license fee plus milestones and royalties), making Dyno the first company to license an AI-designed AAV capsid for both CNS and muscle gene therapies.
  • RocheflagshipStrategic or Co-development Partner · 14 October 2020Roche entered into a collaboration and license agreement with Dyno in October 2020 to apply CapsidMap for CNS and liver-directed AAV gene therapies. Aggregate potential milestone payments may exceed $1.8B. In January 2025, Roche exercised an option to license a Dyno capsid for a neurological disease indication ($7M option fee plus up to $220M+ in milestones plus royalties). In October 2024, the companies entered a new $50M upfront CNS partnership with over $1B in potential milestones plus royalties. Roche is also building on Dyno's LEAP technology.
  • Sarepta TherapeuticsmajorStrategic or Co-development Partner · 11 May 2020Sarepta and Dyno announced a partnership in May 2020 to develop next-generation AAV vectors for muscle diseases using Dyno's CapsidMap platform. Dyno could receive over $40M in upfront, option and license payments during the research phase, with additional significant future milestone payments and royalties on worldwide net sales. Partnership completed in 2025 with improved capsids developed.
  • NovartismajorStrategic or Co-development Partner · 11 May 2020Novartis and Dyno announced an ocular collaboration in May 2020 to develop improved AAV vectors for gene therapies for ocular diseases. Financial terms include upfront consideration, research funding, license fees, clinical and sales milestone payments, and royalties. Partnership completed in 2024 with improved capsids developed.
  • Harvard University / Wyss InstituteflagshipStrategic or Co-development Partner · 1 May 2018Dyno was founded in 2018 on technology developed in George Church's lab at the Wyss Institute for Biologically Inspired Engineering, Harvard Medical School. Dyno has an exclusive option to license the underlying technology from Harvard University, including IP around the comprehensive AAV capsid fitness landscape (Science 2019 publication). George Church, Tomas Bjorklund, and other Harvard scientists serve as Dyno cofounders or scientific advisors.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

Dyno Therapeutics competitors and assessment

Company assessment

Direct peers

  • 4D Molecular Therapeutics: Clinical-stage gene therapy company engineering proprietary AAV capsids (e.g., 4D-150, 4D-710, 4D-175) for ophthalmology, pulmonology, and cardiology. Closest direct competitor to Dyno in machine-guided AAV capsid design, with multiple partnered and wholly-owned programs and similar deal structures.
  • Affinia Therapeutics: AI-driven AAV capsid engineering company developing novel vectors for CNS, muscle, and cardiac indications. Builds engineered capsids using high-throughput data and computation, with similar partnership-plus-pipeline business model to Dyno.
  • Voyager Therapeutics: Clinical-stage gene therapy company that has historically paired its TRACER-derived AAV capsid platform with pharma partners (e.g., Pfizer, Neurocrine, Novartis) for CNS indications. Direct comparability in capsid engineering + partnership model.

Broad incumbents

  • REGENXBIO: Established AAV gene therapy platform company with proprietary NAV technology, extensive licensing business, and a wholly-owned clinical pipeline. Broader incumbent in AAV delivery, providing both licensed vectors (including to Roche, Novartis) and competing capsid IP.
  • uniQure: Commercial-stage gene therapy company with AAV platform technology (HEMGENIX for hemophilia B) and a clinical pipeline in CNS and cardiovascular indications. Comparable gene therapy developer that uses and competes with various AAV capsid technologies.
  • Pfizer (Internal Capsid Programs): Large pharma with significant internal AAV gene therapy programs (e.g., Beqvez for hemophilia B) and internal capsid engineering investments. Represents both a potential customer and a competitive threat to Dyno's partnership pipeline.
  • Roche / Spark Therapeutics: Roche is Dyno's largest partner (>$3B in potential licensing deal value) and Spark is its gene therapy arm (Luxturna). They are simultaneously major customers and developers of competing gene therapy programs using Dyno and third-party capsids.

Emerging players

  • Generate Biomedicines: AI-driven generative biology company designing novel protein therapeutics across multiple modalities. Overlapping AI-for-protein-design platform with Dyno Psi-Phi, though focused on therapeutic proteins rather than AAV delivery.

Others

  • Crary Group / Deciduous Therapeutics (and similar AI-bio peers): Adjacent AI-driven biotech companies backed by Dyno's investor CRV. Representative of the broader AI-bio ecosystem in which Dyno operates and from which it sources investor, developer, and ecosystem partnerships through the Frontiers Network.
  • Andelyn Biosciences: AAV-focused contract development and manufacturing organization (CDMO) and Dyno Frontiers Network manufacturing partner. Comparable ecosystem participant enabling gene therapy manufacturing, and a key distribution and production partner for Dyno's capsids.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Dyno Therapeutics social profiles

Digital presence

Dyno Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dyno Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Dyno Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dyno Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dyno Therapeutics

What does Dyno Therapeutics do?

Dyno Therapeutics applies artificial intelligence and high-throughput in vivo experimentation to design optimized adeno-associated virus (AAV) capsid delivery vectors for gene therapy. The company designs, licenses, and partners AI-engineered capsids targeting the brain, muscle, and eye to gene therapy developers under collaboration and license agreements that include upfront fees, milestone payments, and royalties. Dyno also offers the Dyno Psi-Phi protein design suite, including open-weight generative models and APIs for protein binder design.

Is Dyno Therapeutics a public or private company?

Dyno Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Dyno Therapeutics founded?

Dyno Therapeutics was founded in 2018. It employs 51 to 100 people.

Where is Dyno Therapeutics based?

Dyno Therapeutics is headquartered in Watertown, United States, in the North America region.

How does Dyno Therapeutics make money?

Three revenue lines are on record. Licensing and Milestone Payments from Therapeutic Partners are the primary driver. The others are one-Time License Exercise Fees and royalties on Net Sales.

Who are Dyno Therapeutics's main competitors?

Direct peers on record are 4D Molecular Therapeutics, Affinia Therapeutics and Voyager Therapeutics. Broad incumbents are REGENXBIO, uniQure, Pfizer (Internal Capsid Programs) and Roche / Spark Therapeutics. Generate Biomedicines is listed as an emerging player. Others are Crary Group / Deciduous Therapeutics (and similar AI-bio peers) and Andelyn Biosciences.

Does Dyno Therapeutics have an API?

Yes. Dyno offers community-tier REST APIs branded as 'Dyno Psi-Phi APIs' that provide programmatic access to Dyno Psi-1 (protein binder generation) and Dyno Phi (sequence filtering and experimental grounding). Developers can generate and evaluate protein designs through a unified interface without provisioning GPUs or building custom calibration pipelines, with structure-conditioned design and probabilistic estimation of real-world binding performance. The APIs incorporate NVIDIA BioNeMo NIMs such as OpenFold3. The same APIs are exposed via Dyno Psi-Phi Claude Code Skills as a one-click extension providing authenticated access within Anthropic's Claude Code. APIs are accessible at design.dynotx.com. Developer documentation is at design.dynotx.com.

What industry is Dyno Therapeutics in?

Dyno Therapeutics's product category is AI-Designed AAV Gene Therapy Vectors. Its primary akta.pro industry code is HLAAACAA, AAV Vector Gene Therapy Developers, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogDyno Therapeutics Expands Frontiers Network with Multiple Global Options to Accelerate Path to Clinical Proof of Concept at GATC 2026Dyno Therapeutics expanded its Frontiers Network at GATC 2026 by adding Aurelix Bio, CoJourney, and PrimeRA Pharma as translational partners. The network now offers regional, dual-track clinical-development pathways for gene therapy developers, with over 25 developers served as of November 2026.Business Wire BlogDyno Therapeutics to Present New AAV Capsid Data Across Three Posters at the 33rd Annual Congress of the European Society of Gene & Cell TherapyDyno Therapeutics will present three poster presentations on its AI-engineered AAV capsid platform at the ESGCT Congress in Hamburg, October 27-30, 2026. The data includes dual-mechanism muscle capsids, an ALPL-targeting capsid with cross-species CNS and muscle delivery, and antibody-evasive variants. The company aims to advance gene delivery technologies for therapeutic developers.FinancialContent Business PageDyno Therapeutics Presents New Multi-Mechanism Muscle Capsid Data at the 31st International Congress of the World Muscle SocietyDyno Therapeutics presented preclinical data on AI-designed multi-mechanism capsids at the 31st World Muscle Society Congress, showing improved muscle transduction and low liver biodistribution in mice and non-human primates at 5e12 vg/kg. This dose is 20-fold lower than typical clinical doses, enabling safer advancement of gene therapies for muscular diseases.Business Wire BlogDyno Therapeutics Presents New Multi-Mechanism Muscle Capsid Data at the 31st International Congress of the World Muscle SocietyDyno Therapeutics presented new preclinical data on AI-designed multi-mechanism muscle capsids at the 31st World Muscle Society Congress. At 5e12 vg/kg, the capsids showed 2-fold higher muscle delivery in mice and 20-fold higher in non-human primates versus MyoAAV-4E, with lower liver exposure. The data supports safer advancement of gene therapies for muscular diseases.GlobeNewswireA-Alpha Bio Announces Industry-First Data Consortium to Solve AI Protein Engineering's Experimental Data Bottleneck. Founding members include GSK, Boltz, Cradle, and Dyno Therapeutics.A-Alpha Bio announced the founding members of its Atlas Consortium, an industry-first collaborative model for generating and sharing standardized experimental antibody-antigen data to advance AI-enabled drug discovery, launching with GSK, Boltz, Cradle, and Dyno Therapeutics as founding members. The consortium enables members to design and pool new experimental datasets quarterly through A-Alpha Bio's AlphaSeq platform, providing each member approximately 28 million affinity measurements per year at launch, scaling to 100 million annually as membership grows. The initiative addresses a critical bottleneck in AI protein engineering where high-quality experimental data has been closely guarded, with members quoting that better data and models will accelerate therapeutic development and reduce costs.LinkedInDyno TherapeuticsDyno Therapeutics is actively participating in multiple industry conferences, including the Hope for Rare Foundation Science Conference in Shanghai and BIO2026, to present its advancements in AI-driven gene delivery. The company is also collaborating with NVIDIA Healthcare to develop an infrastructure stack aimed at lowering barriers for genetic medicine development.BioSpaceDyno Therapeutics Announces Expanded Frontiers Network and Second Annual Genetic Agency Technology Conference (GATC)Dyno Therapeutics announced the expansion of its Dyno Frontiers Program into the Dyno Frontiers Network, a curated ecosystem connecting therapeutic developers with capsid technology, manufacturing, development services, and investment partners for genetic medicine development. The company also announced its second annual Genetic Agency Technology Conference (GATC 2026) will be held November 18, 2026 in San Francisco, following an inaugural event that drew 200 attendees. The Network currently comprises 15 therapeutic developers, seven manufacturers, six service providers, and 15 investor partners, with Dyno maintaining strategic collaborations with Astellas and Roche.BioSpaceDyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingDyno Therapeutics announced at the 2026 ASGCT Annual Meeting the launch of two new AI-engineered AAV capsids (Dyno-9zh for CNS delivery and Dyno-n96 for muscle delivery) alongside updated results for existing capsids Dyno-yp2 and Dyno-bn8. The new capsids demonstrate enhanced gene delivery performance in non-human primates, including up to 50% neuronal transduction in the brain and spinal cord, and approximately 74% skeletal myofiber transduction at substantially lower doses than existing gene therapies. The company also expanded its AI platform with open-weight foundation models (Dyno Psi-1) and agentic APIs (Dyno Phi) designed to accelerate cost-effective development of genetic medicines for rare diseases.Business Wire BlogDyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingDyno Therapeutics announced two new AAV capsids, Dyno-9zh and Dyno-n96, for CNS and muscle delivery, plus updated results for Dyno-yp2 and Dyno-bn8, at the ASGCT 2026 meeting. The company also opened its AI platform Dyno Psi-Phi foundation models and agentic APIs for therapeutic developers. The capsids show enhanced transduction and liver detargeting in non-human primate models.DynotxDyno Therapeutics Launches Two New AAV Capsids and AI Platform for Rare Disease Therapeutic Development at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingDyno Therapeutics announced at the 2026 American Society of Gene & Cell Therapy Annual Meeting the launch of two new AAV gene delivery capsids—Dyno-9zh for central nervous system delivery and Dyno-n96 for muscle delivery—alongside updated results for previously released capsids Dyno-yp2 and Dyno-bn8. The company also unveiled advances to its AI platform, including opening Dyno Psi-Phi foundation models and agentic APIs to therapeutic developers and rare disease researchers. These developments expand Dyno's portfolio of AI-engineered vectors designed to improve selective gene delivery while reducing liver biodistribution and enabling scalable manufacturing compatible with existing AAV production processes.